WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012050921) ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/050921    International Application No.:    PCT/US2011/053764
Publication Date: 19.04.2012 International Filing Date: 28.09.2011
IPC:
C07K 14/47 (2006.01), C07K 19/00 (2006.01), A61K 38/17 (2006.01), A61P 25/00 (2006.01), A61P 35/00 (2006.01)
Applicants: NoNO Inc. [CA/CA]; 88 Strath Avenue Toronto, Ontario M8X 1R5 (CA) (For All Designated States Except US).
TYMIANSKI, Michael [CA/CA]; (CA) (For US Only).
LI, Rongwen [CN/CA]; (CA) (For US Only).
GARMAN, Jonathan David [US/CA]; (CA) (For US Only)
Inventors: TYMIANSKI, Michael; (CA).
LI, Rongwen; (CA).
GARMAN, Jonathan David; (CA)
Agent: LIEBESCHUETZ, Joe; Alston & Bird LLP Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, North Carolina 28280-4000 (US)
Priority Data:
61/387,439 28.09.2010 US
Title (EN) ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE
(FR) PEPTIDES ND2 ET PROCÉDÉS DE TRAITEMENT D'UNE MALADIE NEUROLOGIQUE
Abstract: front page image
(EN)The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src. Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.
(FR)La présente invention se base en partie sur l'identification d'une région centrale de ND2 responsable de l'interaction avec Src à l'intérieur des résidus 289 à 321 et plus particulièrement des résidus 310 à 321 de ND2. Des peptides comprenant cette région, la chevauchant ou provenant de l'intérieur de cette région peuvent être utilisés pour inhiber l'interaction avec Src. L'inhibition de cette interaction est utile pour le traitement ou la prophylaxie de maladies et troubles neurologiques, de la douleur et du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)